Heterogeneity of response to biologic treatment: perspective for psoriasis.
Psoriasis treatment responses are affected by patient characteristics. However, the literature does not contain reviews of factors that affect the response to biologic therapies. We therefore performed a comprehensive literature search to identify papers describing demographic, lifestyle, and clinical factors associated with response to biologic drug therapy in psoriatic patients. We found that age, gender, ethnicity, alcohol consumption, smoking, geographic location, age at diagnosis, duration and severity of psoriasis, and baseline C-reactive protein levels did not consistently affect response to biologic psoriasis therapy. However, increased body mass index (BMI) appears to adversely affect responses. It might therefore be valuable to include BMI as a stratification variable in future studies of psoriasis therapies and to consider a patient's weight or BMI when selecting a systemic psoriasis treatment.
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA. Electronic address: eheredia@lilly.com.
Emily
E
Edson-Heredia
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.
Kimberly L
KL
Sterling
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.
Carlos I
CI
Alatorre
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.
Gebra
G
Cuyun Carter
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.
Rosirene
R
Paczkowski
Optum, Eden Prairie, Minnesota, USA.
Victoria
V
Zarotsky
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.
Tomoko
T
Maeda-Chubachi
D000068879:Adalimumab; D000077944:Alefacept; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D001688:Biological Products / Q000627:therapeutic use*; D015992:Body Mass Index; D015897:Comorbidity; D003879:Dermatologic Agents / Q000627:therapeutic use; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D008019:Life Style; D011565:Psoriasis / Q000188:drug therapy* / Q000453:epidemiology*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012307:Risk Factors; D000069549:Ustekinumab
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D003879:Dermatologic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D000069285:Infliximab; D000077944:Alefacept; D000069549:Ustekinumab; D000068879:Adalimumab; D000068800:Etanercept